By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


ChromaDex, Inc. 

10005 Muirlands Boulevard
Suite G, First Floor
Irvine  California  92618  U.S.A.
Phone: 949-419-0288 Fax: 949-419-0294



Company News
ChromaDex, Inc. Presentation Now Available For On-Demand Viewing 10/8/2015 9:56:19 AM
ChromaDex, Inc. To Webcast, Live, At October 1 9/28/2015 12:28:01 PM
Results From First Human Clinical Study Demonstrate ChromaDex, Inc.'s NIAGEN Nicotinamide Riboside Effectively Increases The Co-Enzyme NAD+ And Is Safe 8/12/2015 10:35:48 AM
ChromaDex, Inc. Announces A Collaborative Human Clinical Study On NIAGEN With The University of Colorado Boulder 6/18/2015 7:49:46 AM
ChromaDex, Inc. To Present At The LD Micro Invitational Conference On June 2, 2015 5/20/2015 2:09:40 PM
ChromaDex, Inc. Release: Washington University Medical School Scientists Publish Results Of Pre-Clinical Study Showing Nicotinamide Riboside Is Effective In Rescuing Neurons Subjected To Trauma And Disease 4/29/2015 7:30:19 AM
ChromaDex, Inc. Appoints Former GlaxoSmithKline (GSK) Executive, Jeff Baxter, To Its Board Of Directors 4/20/2015 8:54:22 AM
ChromaDex, Inc. Release: Published Study Shows Topical Treatment With Pterostilbene Effectively Protects Hairless Mice Against UVB Radiation-Induced Skin Damage And Carcinogenesis 4/10/2015 8:29:57 AM
ChromaDex, Inc. Appoints Former Nestle Executive, Steve Allen, As Chairman 3/3/2015 8:48:27 AM
ChromaDex, Inc.'s NIAGEN Nicotinamide Riboside Meets Primary Endpoint In First Human Clinical Study 2/11/2015 7:32:37 AM